Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

141.54 +0.08 (+0.06%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

53 54 Next >

Smokeless Tobacco Treatment Market to See Booming Growth : Novartis, Pfizer, Johnson & Johnson, Cambrex

May 26, 2023

Smokeless Tobacco TreatmentÂ Comprehensive Study by Type (Keratosis Treatment, Addiction Treatment, Disease Treatment), Application (Hospitals & Clinics, Academic & Research Organizations, Pharmacies),...

Via SBWire

The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028

May 26, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END

Via FinancialNewsMedia

Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis ↗

May 22, 2023

Via Benzinga

Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker ↗

May 04, 2023

Eylea sales fell and missed expectations in the U.S.

Via Investor's Business Daily

Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis ↗

May 22, 2023

Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQ: AVRO) are trading higher Monday due to its agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program...

Via Benzinga

Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis ↗

May 22, 2023

Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...

Via Benzinga

Why Is AVROBIO (AVRO) Stock Up 83% Today? ↗

May 22, 2023

AVROBIO (AVRO) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NVS).

Via InvestorPlace

Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market

May 18, 2023

Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth.

Via MarketBeat

Topics Economy

Oral Cancer Treatment Market Projected to Show Strong Growth : Bristol-Myers Squibb, Qilu Pharmaceutical, Novartis

May 15, 2023

Get Oral Cancer Treatment Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.

Via SBWire

Is This Big Pharma Stock a Buy for Dividend Investors? ↗

April 27, 2023

The Swiss pharmaceutical giant possesses a tremendous product pipeline.

Via The Motley Fool

AI for Pharma and Biotech Market Giants Spending Is Going to Boom : PFIZER, Abbott, SANOFI, Atomwise

May 09, 2023

Stay up-to-date with AI for Pharma and Biotech Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Topics Artificial Intelligence

Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance ↗

May 09, 2023

Via Benzinga

What's Going On With Immix Biopharma Stock Today ↗

May 03, 2023

Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'

Via Benzinga

Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents ↗

May 03, 2023

Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several...

Via Benzinga

Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine ↗

May 02, 2023

Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen

Via Benzinga

Why Novartis Stock Is Trading Higher Today ↗

April 25, 2023

Via Benzinga

Earnings Preview: Novartis ↗

April 24, 2023

Via Benzinga

New York Rep. Daniel Goldman Bought Over $50K Worth of Novartis Stock: Here's What You Should Know ↗

April 18, 2023

Via Benzinga

R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

May 02, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

Via FinancialNewsMedia

Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review ↗

April 28, 2023

Microsoft, Meta, Cloudflare and Crocs were among the many big movers.

Via Investor's Business Daily

Rare Blood Disorder Treatment Breakthrough: Novartis' Candidate Improves Hemoglobin To Near-Normal Levels ↗

April 26, 2023

Novartis AG (NYSE: NVS) released detailed

Via Benzinga

After Q1 Review, Novartis Narrows R&D Pipeline To Prioritize High-Value Transformative Medicines ↗

April 25, 2023

In its Q1 FY23 earnings release, Novartis AG (NYSE: NVS) announced cutting its pipeline by around 10% as CEO Vas Narasimhan's campaign to turn it into a "pure-play" drugmaker goes full steam.

Via Benzinga

Novartis Extends Breakout As Three Key Drivers Lead To A Beat-And-Raise ↗

April 25, 2023

Novartis stock popped on its guidance boost early Tuesday after the company beat first-quarter expectations.

Via Investor's Business Daily

3 Top Biotech Stocks Defying the Bear Market ↗

April 25, 2023

All three companies have therapies with strong sales potential.

Via The Motley Fool

Why Legend Biotech Stock Is Having Its Best Month Yet

April 25, 2023

With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.

Via MarketBeat

Novartis Says Relapsing Multiple Sclerosis Patients Remained Free From Disease Progression For Up Five Years With Kesimpta Treatment ↗

April 20, 2023

Via Benzinga

Why Shares of Legend Biotech Jumped Wednesday ↗

April 19, 2023

A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt.

Via The Motley Fool

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland

April 18, 2023

Via Investor Brand Network

2 Best Biotech Stocks to Buy for the Long Haul ↗

April 17, 2023

These two are among the largest pharma companies in the world.

Via The Motley Fool

7 Sorry Pharma Stocks to Sell in April Before It’s Too Late ↗

April 16, 2023

You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards.

Via InvestorPlace

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today